Linked Life Data

15550484

Source:http://linkedlifedata.com/resource/pubmed/id/15550484

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2005-2-17
pubmed:abstractText
Evidence suggests that infusional therapy is a more effective means for administering cytotoxic therapy than intravenous bolus therapy for lymphoma and offers greater potential for therapeutic synergy with rituximab, which has a long half-life. We pooled the results of 3 prospective phase 2 trials evaluating rituximab in combination with 96-hour infusion of cyclophosphamide (187.5-200 mg/m2 per day), doxorubicin (12.5 mg/m2 per day), and etoposide (60 mg/m2 per day) (R-CDE) plus granulocyte-colony-stimulating factor (G-CSF) in 74 patients with HIV-associated, B-cell non-Hodgkin lymphoma, of whom 56 (76%) patients received concurrent highly active antiretroviral therapy (HAART). The complete remission (CR) rate was 70% (95% confidence interval [CI], 59%-81%), and the estimated 2-year failure-free survival and overall survival rates were 59% (95% CI, 47%-71%) and 64% (95% CI, 52%-76%), respectively. Ten (14%) patients had opportunistic infections during or within 3 months of the end of R-CDE, and 17 (23%) patients developed nonopportunistic infections after that time. Six (8%) patients died because of infection; 2 (3%) of those infections were bacterial sepsis during R-CDE, and 4 (5%) were opportunistic infections that occurred between 2 and 8 months after the completion of R-CDE. R-CDE produced a 70% CR rate and a 59% 2-year failure-free survival rate in patients with HIV-associated lymphoma. Consistent with other reports, adding rituximab to cytotoxic therapy in this population may increase the risk for life-threatening infection. Further studies evaluating rituximab in combination with infusional chemotherapy are warranted, but caution is advised.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1891-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:15550484-Adult, pubmed-meshheading:15550484-Aged, pubmed-meshheading:15550484-Antibodies, Monoclonal, pubmed-meshheading:15550484-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:15550484-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15550484-Antiretroviral Therapy, Highly Active, pubmed-meshheading:15550484-Cyclophosphamide, pubmed-meshheading:15550484-Doxorubicin, pubmed-meshheading:15550484-Etoposide, pubmed-meshheading:15550484-Female, pubmed-meshheading:15550484-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:15550484-Humans, pubmed-meshheading:15550484-Infection, pubmed-meshheading:15550484-Infusions, Intravenous, pubmed-meshheading:15550484-Lymphoma, AIDS-Related, pubmed-meshheading:15550484-Lymphoma, B-Cell, pubmed-meshheading:15550484-Male, pubmed-meshheading:15550484-Middle Aged, pubmed-meshheading:15550484-Opportunistic Infections, pubmed-meshheading:15550484-Remission Induction, pubmed-meshheading:15550484-Survival Analysis
pubmed:year
2005
pubmed:articleTitle
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.
pubmed:affiliation
Division of Medical Oncology A, National Cancer Institute, Via Pedemontana Occidentale 12, 33081, Aviano (PN) Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study